A Feasibility Study Of Bevacizumab And Vinorelbine In Patients With Previously Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer
MOLECULAR AND CLINICAL ONCOLOGY(2017)
摘要
The aim of this prospective study was to evaluate the efficacy and feasibility of bevacizumab combined with vinorelbine therapy in patients with previously treated non-squamous non-small-cell lung cancer (nonSq-NSCLC). Patients who had received at least one prior chemotherapy course were eligible for this study. The patients were treated with vinorelbine (25 mg/kg on days 1 and 8) and bevacizumab (15 mg/kg on day 1), which was repeated every 3 weeks until the development of progressive disease or unacceptable toxicity. Between June, 2011 and January, 2013, 15 patients were enrolled. The response and disease control rates were 26.7 and 73.3%, respectively. The median progression-free survival was 2.1 months and the median overall survival was 34.1 months. Grade 3-4 phlebitis occurred in 3 patients. Therefore, the combination of vinorelbine and bevacizumab was found to be effective in patients with previously treated nonSq-NSCLC, but physicians must be aware of the risk of phlebitis associated with this regimen.
更多查看译文
关键词
bevacizumab, vinorelbine, phlebitis
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要